This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DuPont's (DD) Earnings and Revenues Top Estimates in Q1
by Zacks Equity Research
DuPont (DD) gains on higher pricing in Q1 amid headwinds from weak conditions in electronics and construction end markets.
FMC Corp's (FMC) Earnings Top Estimates in Q1, Sales Lag
by Zacks Equity Research
FMC Corp (FMC) benefits from strong pricing actions, growth of new products, expanded market access and cost discipline in Q1.
Should You Invest in the Fidelity MSCI Materials Index ETF (FMAT)?
by Zacks Equity Research
Sector ETF report for FMAT
LyondellBasell (LYB) Q1 Earnings Beat Estimates, Sales Lag
by Zacks Equity Research
LyondellBasell (LYB) witnesses increased global olefins and polyolefins margins driven by reduced ethane cost in the United States, lower energy costs and modestly improved global demand in Q1.
Eastman Chemical's (EMN) Q1 Earnings & Sales Surpass Estimates
by Zacks Equity Research
The top line of Eastman Chemical (EMN) declines due to the challenging global economic environment owing to higher-than-normal customer inventory destocking in Q1.
U.S. Steel's (X) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Lower prices across Flat-Rolled, Mini Mill and U.S. Steel Europe units hurt U.S. Steel's (X) results in the first quarter.
International Paper (IP) Q1 Earnings Beat Estimates, Down Y/Y
by Zacks Equity Research
International Paper's (IP) Q1 earnings decline year on year, reflecting the ongoing customer inventory destocking.
Linde's (LIN) Q1 Earnings Beat Estimates on Higher Prices
by Zacks Equity Research
Increased prices and volumes across beverage and manufacturing and food end markets aid Linde's (LIN) Q1 earnings.
Compared to Estimates, Linde (LIN) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Linde (LIN) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Methanex's (MEOH) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Lower average realized prices on a year-over-year basis hurt Methanex's (MEOH) Q1 earnings.
Element Solutions (ESI) Q1 Earnings Beat Estimates, Sales Lag
by Zacks Equity Research
Element Solutions (ESI) faces headwinds from the weakening of demand in smartphones and the broader electronic supply chain in Q1.
Newmont's (NEM) Q1 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
Higher costs and lower gold production hurt Newmont's (NEM) first-quarter performance.
LyondellBasell (LYB) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
LyondellBasell (LYB) first-quarter results are likely to reflect soft demand due to a challenging operating environment and moderate feedstock and energy costs.
Is a Surprise Coming for Linde (LIN) This Earnings Season?
by Zacks Equity Research
Linde (LIN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ecolab (ECL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Ecolab (ECL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dow (DOW) Earnings and Revenues Trounce Estimates in Q1
by Zacks Equity Research
Lower local prices and volumes as well as weaker global macroeconomic activities hurt Dow's (DOW) top line in Q1.
Cleveland-Cliffs (CLF) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
The demand recovery in automotive markets aids Cleveland-Cliffs' (CLF) Q1 performance.
Is a Beat in the Offing for Linde (LIN) in Q1 Earnings?
by Zacks Equity Research
Higher industrial production in the March quarter is likely to have aided Linde's (LIN) Q1 earnings.
The Zacks Analyst Blog Highlights Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI
by Zacks Equity Research
Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI are included in this Analyst Blog.
Top Stock Reports for Linde, Vertex Pharmaceuticals & Edwards Lifesciences
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Linde plc (LIN), Vertex Pharmaceuticals Incorporated (VRTX) and Edwards Lifesciences Corporation (EW).
Linde (LIN) Notifies Capacity Expansion of South Korea Facility
by Zacks Equity Research
Linde (LIN) expands its on-site plant's capacity in South Korea with twin goals of providing industrial gases to its major customer, Samsung Display, and meeting the region's growing electronic needs.
Freeport's (FCX) Earnings Top Estimates in Q1, Revenues Lag
by Zacks Equity Research
Freeport's (FCX) Q1 earnings surpass estimates despite challenges from lower copper prices, reduced copper sales volumes from PT-FI and disruptions from a significant weather event.
PPG Industries (PPG) Q1 Earnings Beat Estimates, Sales Lag
by Zacks Equity Research
Higher pricing across segments, improved manufacturing efficiencies and overall cost discipline drive PPG Industries' (PPG) Q1 earnings.
Linde (LIN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Linde (LIN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nucor's (NUE) Earnings and Revenues Surpass Estimates in Q1
by Zacks Equity Research
Nucor (NUE) sees higher earnings in its steel mills unit on a sequential comparison basis in Q1 on higher volumes and margins.